Cover Story: A Breakthrough for Industry and Patients
On 30 August, the FDA approved Novartis’s Kymriah, the first gene therapy for the treatment of pediatric and young-adult patients with relapsed and refractory ALL. Kymriah belongs to a class of drugs called CAR T-cell therapies, a form of immunotherapy that redirects the body’s T-cells to attack tumors. This is the first FDA-approved gene-transfer therapy, but there are a number of other CAR T-cell products in development.
Feature: Patent Battles in the Age of CRISPR
CRISPR’s power lies in its relative simplicity and precision, and it is expected to have profound implications for agriculture and the treatment of disease. No surprise, then, that the groundbreaking technology is already beset with controversy ranging from ethical issues associated with the technology to a highly publicized and public US patent dispute.
Special Report: Setting the Course for Biopharma’s Future
While biopharmaceutical drugs have become standard therapy for multiple diseases, they require new manufacturing techniques both at the facility and throughout the supply network. When combined with changes in biopharmaceutical portfolios, these new technologies will create both challenges and opportunities for biopharmaceutical companies